Stockreport

Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

Solid Biosciences Inc.  (SLDB) 
Last solid biosciences inc. earnings: 8/14 07:25 am Check Earnings Report
US:NASDAQ Investor Relations: investors.solidbio.com/investor-relations
PDF – SGT-212 has been granted FDA Rare Pediatric Disease and Fast Track designations – – SGT-212 is the only dual route gene therapy in development to treat Friedreich’s a [Read more]